Arnulf, B.
488  results:
Search for persons X
?
2

Rituximab with alkylating agent in anti‐myelin‐associated g..:

Elessa, D. ; Grosjean, V. ; Lozeron, P....
British Journal of Haematology.  204 (2024)  6 - p. 2484-2486 , 2024
 
?
3

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSE..:

Nooka, A ; Lesokhin, A ; Mohty, M...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S405 , 2023
 
?
5

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANT..:

Mohty, M ; Tomasson, M ; Arnulf, B...
Hematology, Transfusion and Cell Therapy.  45 (2023)  - p. S404-S405 , 2023
 
?
 
?
10

A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN..:

Lesokhin, AM ; Arnulf, B ; Niesvizky, R...
Hematology, Transfusion and Cell Therapy.  44 (2022)  - p. S245-S246 , 2022
 
?
11

Perioral skin thickening revealing AL amyloidosis:

Billard, K. ; Arnulf, B. ; Kottler, D....
Journal of the European Academy of Dermatology and Venereology.  36 (2022)  9 - p. , 2022
 
?
13

Syndrome POEMS : diagnostic, prise en charge et traitements:

Talbot, A. ; Jaccard, A. ; Arnulf, B.
La Revue de Médecine Interne.  42 (2021)  5 - p. 320-329 , 2021
 
?
14

Prognostic value of cardio-pulmonary exercise testing in ca..:

Nicol, M. ; Deney, A. ; Lairez, O....
Archives of Cardiovascular Diseases Supplements.  13 (2021)  1 - p. 28 , 2021
 
?
15

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE..:

Einsele, H ; Parekh, S ; Madduri, D...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S263-S264 , 2021
 
1-15